License and Collaboration Agreements - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Oct. 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Product revenues, net	$ 207,774	$ 166,911	$ 607,836	$ 433,676
Settlement charge	0	0	0	10,000
Research, option and milestone expense	0	0	6,000	3,000
Up-front and development milestone expenses	5,500		14,300
Henogen SA [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development expenses charges			17,100
Collaborative Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payment for option exercise			188,600
Up-front and development milestone expenses		0		0
Collaborative Arrangement | Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contingent research milestone payments			7,000
Development Milestone and Settlement Upfront Fee Recognized as Research and Development Expense	4,100,000		4,100,000
Collaborative Arrangement | Research and Development Expense [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Up-front and development milestone expenses	5,000	4,500	5,000	50,200
Collaborative Arrangement | Roche Holding A.G. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Product revenues, net	22,500	66,800	22,500	66,800
Deferred Revenue	596,700		596,700
Deferred Revenue, Current	89,200		89,200
Deferred Revenue Separate Material Options Right	485,000		485,000		$ 485,000
Research and development expense	22,000	$ 29,400	66,100	$ 60,800
Collaboration Receivable	21,900		$ 21,900
Equity Investment Agreement [Member] | Lysogene S.A. [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development, regulatory and sales milestones payments to be paid						$ 102,800
Common stock purchased,shares			1,140,728
Equity Investment Agreement [Member] | Lysogene S.A. [Member] | Other Noncurrent Assets [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Equity investment publicly traded security	$ 700		$ 700